4-(methoxymethoxy)benzoyl chloride | 169900-06-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(methoxymethoxy)benzoyl chloride
• CAS: 169900-06-5
• 化学式: C₉H₉ClO₃
• 分子量: 200.622
• InChiKey: DXBLJHMCZMPCMS-UHFFFAOYSA-N

物化性质

• 沸点：
  294.4±20.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(methoxymethoxy)benzoyl chloride 在 盐酸 、 sodium chlorite 、 氨基磺酸 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 58.0h， 生成 trans-1-[4-(2-hydroxycarbonyl-6-hydroxybenzoyl)-3,5-dihydroxybenzyloxy]-2-(4-hydroxybenzamido)cyclopentane
  参考文献：
  名称：

  Synthesis and Protein Kinase Inhibitory Activity of Balanol Analogues with Modified Benzophenone Subunits

  摘要：

  A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits are described. The analogues were designed with the goal of uncovering structure - activity features that could be used in the development of PKC inhibitors with a reduced polar character compared to balanol itself. The results of these studies suggest that most of the benzophenone features found in the natural product are important for obtaining potent PKC inhibitory compounds. However, several modifications were found to lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modifications to the polar structural elements of the benzophenone were found to provide potent PKC inhibitors. In particular, it was found that replacement of the benzophenone carboxylate with bioisosteric equivalents could lead to potent analogues. Further, a tolerance for lipophilic substituents on the terminal benzophenone ring was uncovered. These results are discussed in light of recently available structural information for PKA.

  DOI：

  10.1021/jm020018f
• 作为产物：
  描述：

  4-(methoxymethoxy)benzoic acid methoxymethyl ester 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 27.5h， 生成 4-(methoxymethoxy)benzoyl chloride
  参考文献：
  名称：

  Synthesis and Protein Kinase Inhibitory Activity of Balanol Analogues with Modified Benzophenone Subunits

  摘要：

  A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits are described. The analogues were designed with the goal of uncovering structure - activity features that could be used in the development of PKC inhibitors with a reduced polar character compared to balanol itself. The results of these studies suggest that most of the benzophenone features found in the natural product are important for obtaining potent PKC inhibitory compounds. However, several modifications were found to lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modifications to the polar structural elements of the benzophenone were found to provide potent PKC inhibitors. In particular, it was found that replacement of the benzophenone carboxylate with bioisosteric equivalents could lead to potent analogues. Further, a tolerance for lipophilic substituents on the terminal benzophenone ring was uncovered. These results are discussed in light of recently available structural information for PKA.

  DOI：

  10.1021/jm020018f

文献信息

• [EN] AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION<br/>[FR] DÉGRONIMÈRES DE C3-GLUTARIMIDE LIÉS À UNE AMINE POUR LA DÉGRADATION DE PROTÉINES CIBLES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2017197051A1

  公开（公告）日：2017-11-16

  This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

  这项发明提供了胺连接的C3-戊二酰亚胺Degronimers和Degrons，用于治疗应用，如本文进一步描述的，以及它们的使用方法、组合物以及它们的制备方法。
• AMIDE DERIVATIVE
  申请人：TOHOKU UNIVERSITY

  公开号：US20160368860A1

  公开（公告）日：2016-12-22

  The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

  本发明提供了一种用于治疗和/或预防与增加OPN产生相关的疾病，包括癌症的有用药物，其包括以下公式的化合物：其中R1、R2、R3、R4、R5、R6、R7、m、n、p、X和Y如规范中定义，其药学上可接受的盐。
• Thieme Chemistry Journals Awardees – Where Are They Now? Bis(2-pyridyl)amides as Readily Cleavable Amides Under Catalytic, Neutral, and Room-Temperature Conditions
  作者：Naoya Kumagai、Masakatsu Shibasaki、Shinya Adachi

  DOI：10.1055/s-0036-1590932

  日期：2018.2

  Mild solvolytic cleavage of bis(2-pyridyl)amide under neutral and room-temperature conditions is described. The inherently stable amide was readily activated by catalytic amounts of metal cations to react with alcohols. Based on X-ray crystallographic analysis, the primary driving force was considered to be amide distortion induced by the metal coordination of two pyridyl groups in a bidentate fashion

  描述了双 (2-吡啶基) 酰胺在中性和室温条件下的温和溶剂裂解。固有稳定的酰胺很容易被催化量的金属阳离子活化，与醇反应。基于 X 射线晶体学分析，主要驱动力被认为是由两个吡啶基以双齿方式金属配位引起的酰胺畸变，而不影响酰​​胺官能度。酸/碱敏感功能的兼容性和溶剂分解过程中没有外消旋化突出了本协议的温和性。
• AMIDE DERIVATIVES
  申请人：Tohoku University

  公开号：EP3112343A1

  公开（公告）日：2017-01-04

  The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种用于治疗和/或预防与 OPN 生成增强有关的疾病（包括癌症）的有用药物，它包括一种式化合物： 其中 R1、R2、R3、R4、R5、R6、R7、m、n、p、X 和 Y 如说明书中所定义，或其药学上可接受的盐。
• Amide derivative
  申请人：TOHOKU UNIVERSITY

  公开号：US11040937B2

  公开（公告）日：2021-06-22

  The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

  本发明提供了一种用于治疗和/或预防与 OPN 生成增强有关的疾病（包括癌症）的有用药物，它包括一种式化合物： 其中R1、R2、R3、R4、R5、R6、R7、m、n、p、X和Y如说明书中所定义，其为药学上可接受的盐。